OA02.4. Pathologic Response Predicts Survival After Neoadjuvant Chemotherapy for Esophageal Adenocarcinoma: A Propensity-Matched Analysis
Diseases of the Esophagus · 22.08.2026 · 39 (Supplement_1)
DOI: 10.1093/dote/doag077.016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diseases of the Esophagus, online erschienen am 22.08.2026. Verfasst von Nianye Zhang und 8 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Perioperative chemotherapy (CT) is increasingly replacing chemoradiotherapy (CRT) for the treatment of esophageal adenocarcinoma, although CRT is associated with higher rates of pathologic complete response (pCR). Whether degree of pathologic regression, beyond binary pCR status, independently predicts survival and whether treatment strategy modifies this relationship remain unclear in real-world practice.
Methods
We retrospectively analyzed adults with resectable locally advanced esophageal or gastroesophageal junction adenocarcinoma who underwent esophagectomy (January 2013 to October 2024) following induction CRT or perioperative CT ± immunotherapy (IO). To address baseline imbalances, propensity-score matching (1:1) was performed. Disease-free survival (DFS) was estimated using Kaplan-Meier methods and compared with log-rank tests. In the full unmatched cohort, percent pathologic tumor regression was modeled as a continuous variable in multivariable Cox regression to assess its independent association with overall survival (OS) and to test for interaction with treatment strategy. All analyses were performed using R version 4.5.0.
Results
Among 811 patients (CRT, n=650; CT ± IO, n=161), median follow-up was 29.9 months. CRT was associated with a higher rate of pCR (23% vs 14%; p=0.013) and ypN0 (61% vs 46%; p<0.001). In the full cohort (n=811), each 10% increase in pathologic tumor regression was independently associated with longer OS (hazard ratio, 0.89 [95% confidence interval, 0.84-0.94]; p<0.001); this was consistent across treatment groups (interaction p=0.230) (Figure 1). In the propensity-matched cohort (n=294), baseline characteristics were well balanced. There was no difference in OS between CT ± IO and CRT (p=0.097). Among patients without pCR, DFS was significantly longer with CT ± IO (p=0.027); DFS was not statistically different among patients with pCR (p=0.18) (Figure 2).
Conclusion
Degree of pathologic regression is independently associated with survival; this finding supports a graded prognostic effect beyond binary pCR status. Perioperative CT ± IO was associated with longer DFS, compared with CRT, in patients without pCR. These findings suggest that locoregional response alone does not fully capture treatment benefit and support the hypothesis that systemic therapy–intensified strategies may enhance micrometastatic control.
Zitieren
APA
Zhang, N., Alkaaki, A., Chen, S., Park, B., Jones, D., Gray, K., Bott, M., Sihag, S., & Molena, D. (2026). OA02.4. Pathologic Response Predicts Survival After Neoadjuvant Chemotherapy for Esophageal Adenocarcinoma: A Propensity-Matched Analysis. Diseases of the Esophagus, 39(Supplement_1). https://doi.org/10.1093/dote/doag077.016
Vancouver
Zhang N, Alkaaki A, Chen S, Park B, Jones D, Gray K, et al. OA02.4. Pathologic Response Predicts Survival After Neoadjuvant Chemotherapy for Esophageal Adenocarcinoma: A Propensity-Matched Analysis. Diseases of the Esophagus. 2026;39(Supplement_1). doi:10.1093/dote/doag077.016
BibTeX
@article{Zhang2026,
author = {Zhang, Nianye and Alkaaki, Aroub and Chen, Siqi and Park, Bernard and Jones, David and Gray, Katherine and Bott, Matthew and Sihag, Smita and Molena, Daniela},
title = {OA02.4. Pathologic Response Predicts Survival After Neoadjuvant Chemotherapy for Esophageal Adenocarcinoma: A Propensity-Matched Analysis},
journal = {Diseases of the Esophagus},
year = {2026},
volume = {39},
number = {Supplement_1},
doi = {10.1093/dote/doag077.016}
}
EUVIMED